Serca–VivarRios COVID-19 vaccine: Difference between revisions
No edit summary |
No edit summary |
||
| Line 9: | Line 9: | ||
| type = {{wpl|Viral vector vaccine|Viral vector}} | | type = {{wpl|Viral vector vaccine|Viral vector}} | ||
| inventor = Serca Circuit University<br>VivarRios Pharmaceuticals | | inventor = Serca Circuit University<br>VivarRios Pharmaceuticals | ||
| inception = December {{start date|2020}} | | inception = 22 December {{start date|2020}} | ||
| manufacturer = VivarRios Pharmaceuticals | | manufacturer = VivarRios Pharmaceuticals | ||
| available = Approved in Carloso and many other countries | | available = Approved in Carloso and many other countries | ||
Revision as of 12:46, 26 April 2021
 | This article or section is in the process of an expansion or major restructuring. You are welcome to assist in its construction by editing it as well. If this article or section has not been edited in several days, please remove this template. If you are the editor who added this template and you are actively editing, please be sure to replace this template with {{in use}} during the active editing session. Click on the link for template parameters to use.
This article was last edited by Greater Carloso (talk | contribs) 3 years ago. (Update timer) |
 | |
| Type | Viral vector |
|---|---|
| Inventor | Serca Circuit University VivarRios Pharmaceuticals |
| Inception | 22 December 2020 |
| Manufacturer | VivarRios Pharmaceuticals |
| Available | Approved in Carloso and many other countries |
The Serca–VivarRios COVID-19 vaccine is a Carlosian viral vector vaccine against the COVID-19 disease. It was developed as a result of a collaboration between Serca Circuit University and VivarRios Pharmaceuticals. It is injected intramuscularly in two doses, with a 12 week interval. Trials conducted across Carloso and several other countries in Musgorocia indicate 82.4% efficacy in preventing symptomatic COVID-19, increasing to 91.5% after the second dose. It has the advantage over other vaccines of only needing to be stored at normal refrigerated temperatures (2–8 °C). It is in widespread use across Musgorocia.
It has been the subject of unfounded conspiracy theories and misinformation campaigns supported by enemies of the Carlosian government, including Bourgougia and domestic political opponents. Baseless claims have included a supposed heightened risk of blood clotting in younger people, seizures and lower efficancy among certain age groups. Production of the vaccine has been supported by the Carlosian government and batches are sold at below cost. Starting in March 2021, the Carlosian Armed Forces have begun transporting millions of doses of the Serca–VivarRios vaccine to developing countries as foreign aid. There are plans for VivarRios Pharmaceuticals to enter agreements with domestic suppliers to accelerate production and worldwide access.
The technology used in the development of this vaccine is currently being utilised in the development of a vaccine against Clostroides abaddoni bacterial infection 2019 (CaBI19). It is currently in Phase III clinical trials.